Related Stories

Earendil Labs Announces First Patient Dosed in a Phase IIa Trial of a Half-life Extended Anti-TL1A Antibody (HXN-1001) in Patients with Ulcerative Colitis

Earendil Labs Announces First Patient Dosed in a Phase IIa Trial of a Half-life Extended Anti-TL1A Antibody (HXN-1001) in Patients with Ulcerative Colitis

2026/04/02/20:53:56
IFS Breaks with Industry Convention Pricing to Unlock Enterprise-Wide AI Adoption

IFS Breaks with Industry Convention Pricing to Unlock Enterprise-Wide AI Adoption

2026/04/02/19:53:58
Yonyou AI Lab Introduces Framework to Make Enterprise AI Decisions Traceable and Auditable

Yonyou AI Lab Introduces Framework to Make Enterprise AI Decisions Traceable and Auditable

2026/04/02/19:53:58

You may have missed

Earendil Labs Announces First Patient Dosed in a Phase IIa Trial of a Half-life Extended Anti-TL1A Antibody (HXN-1001) in Patients with Ulcerative Colitis

Earendil Labs Announces First Patient Dosed in a Phase IIa Trial of a Half-life Extended Anti-TL1A Antibody (HXN-1001) in Patients with Ulcerative Colitis

2026/04/02/20:53:56
Yonyou AI Lab Introduces Framework to Make Enterprise AI Decisions Traceable and Auditable

Yonyou AI Lab Introduces Framework to Make Enterprise AI Decisions Traceable and Auditable

2026/04/02/19:53:58
IFS Breaks with Industry Convention Pricing to Unlock Enterprise-Wide AI Adoption

IFS Breaks with Industry Convention Pricing to Unlock Enterprise-Wide AI Adoption

2026/04/02/19:53:58
乘”云”出海，智赢全球：IBM公有云护航中国企业全球化新征程 乘"云"出海，智赢全球：IBM公有云护航中国企业全球化新征程

乘”云”出海，智赢全球：IBM公有云护航中国企业全球化新征程

2026/04/02/19:53:55
Share via
Facebook
X (Twitter)
LinkedIn
Mix
Email
Print
Copy Link
Copy link
CopyCopied